CANVAS Program

INVOKANA^® (canagliflozin) Prescribing Information can be found under Useful Links

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

CANVAS: Canagliflozin Cardiovascular Assessment Study

The CANVAS program consisted of two large-scale clinical trials: CANVAS and CANVAS-R. Conducted to evaluate the cardiovascular outcomes of canagliflozin in patients with type 2 diabetes.^5,11

Red-Lozenge-1

Red-lozenge-2

Invokana-Diagram-5

Red-Lozenge-3638245029354955034

Red-Lozenge-4638245030745433841

Results

In the two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo.

Primary Outcomes

Invokana-Diagram-11638245027323296588

MACE

Major
Averse
Cardiovascular
Event

The addition of Invokana to standard of care resulted in significant reductions in DKD progression vs placebo

Abbreviations
CI– Confidence Interval
ESKD – End Stage Kidney Disease
HHF – Hospitalisation for Heart Failure
HR – Hazard Ratio
MACE – Major Adverse Cardiovascular Event
NNT – Number Needed to Treat
RRR – Relative Risk Reduction
UACR – Urinary Albumin-to-Creatinine Ratio

PP-IN-UK-0198 July 2023